Kornimate/medical-research-clean huggingface dataset:
a randomized controlled trial of the intake of organic and inorganic phosphate in peritoneal dialysis patients

Conditions: Chronic Kidney Disease Requiring Chronic Dialysis

Summary: hyperphosphatemia is a common problem among patientens suffering from chronic kidney disease. hyperphosphatemia is associated with increased risk of cardiovascular diseases. one of the treatments are through the diet, where patients are instructed ind reducing their daily intake of phosphate. but since phosphate exists in both organic and inorganic forms in the diet, this leads to several problems. informations of the bioavability and furthermore the effect of plasma koncentrations of phosphate are lacking for both forms of phosphate.


Eligibility criteria:
inclusion criteria: * patients \> 18 years * competent * the patient should be able to take a sample of p-fluid and urine by himself * chronic peritoneal dialysis * reads and understand danish * has been informed written and oraly about the study and signed informed consent * p-phosphate koncentrations 0,7-2,0 .mol/l * p - ioniset calcium 1,1-1,4 mmol/l exclusion criteria: * pregnant or breast-feeding * terminal patients * if the experience acute infections or other acute situations they will be excluded from the study
a non-randomized controlled trial was conducted to observe the improvement in the level of hama in patients with generalized anxiety disorder during the 6-week period of oral treatment with chaihu jia longgu muli tang (bupleurum plus dragon bone and oyster shell decoction) combined with sertraline.

Conditions: Generalised Anxiety Disorder

Summary: the purpose of this study is to clinically observe the efficacy of bupleurum plus dragon bone and oyster shell decoction in the treatment of generalized anxiety disorder to improve the scores of hama

generalized anxiety disorder, not only results in a disturbed psychological condition, but even daily life with coworkers and family will also be disrupted. chaihu jia longgu muli tang (bupleurum plus dragon bone and oyster shell decoction), a compound chinese herbal medicine found in "treatise on cold damage", has been used for treating mental disorders with symptoms such as chest distress, irritability, being frightened, etc since the china han dynasty. in this study, we will observe the efficacy of this formula, in order to provide an evidence-based basis for clinical observation and evaluation of generalized anxiety disorder.

Eligibility criteria:
inclusion criteria: * meets the western medical diagnostic criteria for generalized anxiety disorder; * the tcm diagnosis is heat-depressed on shao-yang (rè yù shǎo yáng) type; * hamilton anxiety scale (hama) score ≥ 7; * age 18-80 years old. exclusion criteria: * allergy to chinese medicine formulas; * pregnant or breastfeeding; * suicidal ideation and suicide attempt; * substance use disorders; * severe cardiovascular diseases liver diseases and kidney diseases.

Keywords: generalized anxiety disorder chaihu jia longgu muli tang sertraline heat-depressed on shao-yang
[18f]mc225-pet in neurodegenerative disease

Conditions: Neurodegenerative Diseases; Alzheimer Disease; Parkinson Disease; Mild Cognitive Impairment

Summary: p-glycoprotein, an efflux transporter at the blood-brain barrier plays an important role in de development of neurodegenerative disease. a novel pet tracer (\[18f\]mc225) was developed to measure the function of p-glycoprotein and was tested with succes in healthy volunteers. this study aims to evaluate \[18f\]mc225 in neurodegenerative disease.

a decrease in p-glycoprotein (p-gp) function is associated with the onset of neurodegenerative disease. new treatment strategies in neurodegenerative disease, including parkinson's disease and alzheimer's disease, aim to restore the p-gp function. to evaluate the effect of these potential therapies, measurement of the p-gp function is necessary. up until now \[11c\]verapamil is considered to be the gold standard to measure p-gp function. however tracer uptake in the brain of \[11c\]verapamil is too low for adequate measurement of treatment effect, especially of restoring p-gp function. a novel pet tracer to measure p-gp function, \[18f\]mc225, has the potential advantage of higher brain uptake values at baseline and might therefore able to measure both up- and down regulation p-gp function. \[18f\]mc225 was recently studied in healthy volunteers and a method to quantify p-gp function was developed. this study aims to evaluate \[18f\]mc225 to measure p-gp function in neurodegenerative disease. to this aim 10 mci patients, 10 patients with alzheimer's disease and 10 parkinson's disease patients will be included and undergo one 60 min dynamic \[18f\]mc225 pet scan, combined with a 10 min \[15o\]h2o pet. tracer uptake values (vt) and influx (k1) in several brain regions of interest, representing local p-gp function will be compared with the \[18f\]mc225 uptake values in the brain of healthy volunteers obtained in a previous study.

Eligibility criteria:
inclusion criteria: * patient is diagnosed with alzheimer's disease, parkinson's disease or mild cognitive impairment exclusion criteria: * use of any medication influencing the p-glycoprotein function * history of neuropsychiatric disorders * contra-indications mri * allergy contrast agent

Keywords: pet pharmacokinetic modeling [18f]mc225
eeva™ continued access study: assessing the usability of eeva in a clinical setting

Conditions: Infertility

Summary: user questionnaire of eeva system usability and reports of device malfunctions.

this study is designed to evaluate the use of eeva by ivf laboratory staff during routine procedures. the fertilized eggs will be placed in an eeva dish and the development of the embryos will be monitored by the eeva system in a standard incubator. on day 3 of embryo culture, eeva blastocyst prediction data will be printed from the system to be used to assist the embryologist in selecting the best embryo(s). the performance of the system will be summarized and the user feedback from the embryologists will be collected.

Eligibility criteria:
inclusion criteria: * women undergoing fresh in vitro fertilization treatment using their own eggs or donor eggs * subject is ≥ 18 and ≤ 40 years of age. * subject has basal antral follicle count (afc) ≥ 8 prior to stimulation cycle. * fertilization using only ejaculated sperm (fresh or frozen) - no surgically retrieved sperm. * subject has ≥ 5 normally fertilized eggs (2 pn) * willing to have all 2pn embryos monitored by eeva * willing to comply with study protocol and procedures and able to speak english. * willing to provide written informed consent. exclusion criteria: * reinseminated eggs. * history of cancer. * gestational carriers. * planned preimplantation genetic diagnosis or preimplantation genetic screening. * previously enrolled in this study * concurrent participation in another clinical study.

Keywords: in vitro fertilization assisted reproduction noninvasive imaging of embryos time lapse imaging of embryos traditional morphological grading of embryos prediction of blastocysts infertility genital diseases, male genital diseases, female
nasopharyngeal carcinoma screening in zhongshan city

Conditions: Nasopharyngeal Carcinoma

Summary: the primary objective is to determine the early diagnosis rate and mortality rate of the nasopharyngeal carcinoma (npc) in the study population. the secondary objective is to determine the incidence of npc in the study population.

the research is to evaluate the effect of npc screening, also as an extended study of screening for nasopharyngeal carcinoma in high risk populations (nct00941538). the program was conducted in xiaolan and minzhong towns of zhongshan city in 2012. all participants will be tested for anti-ebv antibody by using serum samples. participants are stratified into those having high, moderate and low antibody levels, those having moderate antibody levels are invited to retest annually in the following 3 years and those found to have high antibody levels on these occasions are referred to centers for diagnostic workup for npc.

Eligibility criteria:
inclusion criteria: * subject residents in zhongshan city * subject is 30 to 59 years of age inclusive * subject has no medical record of nasopharyngeal carcinoma * ecog 0-2 * subject has psychical condition and well consciousness * subject is able to comprehend, sign, and date the written informed consent document to participate in the study. exclusion criteria: * subject has heavy cardiovascular, liver or kidney disease * subject has medical record of nasopharyngeal carcinoma * subject who is not residing in zhongshan city
abcb5 as a prognostic marker in survival of cultivated limbal stem cell transplantation

Conditions: Limbal Stem Cell Deficiency

Summary: in this study the prognostic value of abcb5 in survival of the limbal stem cell transplantation expanded in vitro on amniotic membrane for corneal surface reconstruction in patients with limbal stem cell deficiency will be analyzed.

there are several diseases that cause the cornea to lose its clarity and directly affects the vision of the individual, therefore, the use of limbal stem cells has been having increasing acceptance in the field of medical therapy. an open clinical study is running with patients with limbal stem cell deficiency, performing a limbal stem cell transplantation expanded in vitro on amniotic membrane and the value of abcb5 as a prognostic factor in the survival of transplant will be determined. the corneal surface status will be the primary endpoint.

Eligibility criteria:
inclusion criteria: 1. bilateral limbal stem cell deficiency of any etiology. 2. corneal impression cytology positive for goblet cells. 3. ocular ultrasound results within normal parameters. 4. agree to participate in the study and sign the informed consent. exclusion criteria: 1. active immunological diseases.

Keywords: cornea limbal stem cell
cardiac rehabilitation for patients receiving radiation therapy for thoracic cancers

Conditions: Lung Cancer; Esophageal Cancer; Thoracic Cancer; Hodgkin Lymphoma; Hodgkin Disease; Non-hodgkin Lymphoma; Sarcoma; Thymoma; Breast Cancer

Summary: other than optimizing medical management of cardiac risk factors, and reducing radiotherapy (rt) dose to the heart, there currently exist no interventions to mitigate or reverse the adverse cardiac effects of rt. aerobic exercise has been demonstrated to improve patient quality of life, cardiac outcomes, and cardiorespiratory fitness in patients with cancer receiving cardiotoxic systemic therapies, but the effects of aerobic exercise on patients at high risk for radiation induced heart disease (rihd) is unknown. in addition, home-based cardiac rehabilitation has not been tested in patients with thoracic cancers.


Eligibility criteria:
inclusion criteria: * pathologically confirmed or radiographically diagnosed non-small cell lung cancer, small cell lung cancer, esophageal cancer, hodgkin lymphoma, non-hodgkin lymphoma, sarcoma, thymoma, or left-sided breast cancer. * planning to receive neo-adjuvant, adjuvant, or definitive radiation therapy to the thorax with curative intent. * willing to participate in home-based cardiac rehabilitation program and be monitored remotely via smart phone application * possess a smart phone or tablet capable of supporting teleheart application * willing and eligible to co-enroll in the cardiovascular toxicity in cancer and improvement in recovery (survive) registry study (hrpo# 201801031). * at least 18 years of age. * ecog performance status ≤ 2 * ability to understand and willingness to sign an irb approved written informed consent document (or that of legally authorized representative, if applicable). exclusion criteria: * presence of distant metastatic disease (except patients with lymphoma). * life expectancy less than 6 months * patient lives in skilled nursing facility, chronic care facility, nursing home, or palliative care or hospice facility * unable to walk * presence of significant cancer disease burden that would make patient unlikely to tolerate cardiac rehabilitation (cr) * diagnosis of primary cervical esophageal cancer. * presence of unstable angina. * recipient of heart transplant. * patient on cardiac transplant list or has a ventricular assist device * patient's baseline weight \> 300 lbs (due to weight limitations of the scale and bioelectrical impedance device) * pregnant and/or breastfeeding. women of childbearing potential must have a negative pregnancy test within 14 days of study entry. * other medical comorbidities that make the patient unable to participate in the cr program or other assessments involved with this study.
a study of fmt in patients with aml allo hsct in recipients

Conditions: Acute Myeloid Leukemia; Allogeneic Hematopoietic Cell Transplantation

Summary: this is a randomized, double-blind, placebo-controlled clinical trial of fecal microbiota transplant (fmt) in 2 independent cohorts (60 acute myeloid leukemia patients undergoing intensive chemotherapy and 60 allo-hct patients). participants in each cohort will be randomized in a 2:1 ratio to receive up to 3 treatments of fmt vs. placebo after each exposure to antibacterial antibiotics until 3 months after randomization.


Eligibility criteria:
inclusion criteria: * age≥ 18 years * cohort a: patients undergoing intensive induction chemotherapy for acute myeloid leukemia (aml; newly diagnosed or relapsed/refractory). \* any intensive regimen with planned \~4 weeks of inpatient stay * cohort b: allo-hct patients \* any allogeneic transplant regimen with planned gvhd prophylaxis containing generic iv mycophenolate mofetil (mmf) and tacrolimus (tac) * sexually active females of childbearing potential and males with partners of child-bearing potential must agree to use adequate birth control until at least six months post-fmt/placebo * voluntary written consent signed before performance of any study-related procedure not part of normal medical care exclusion criteria: * planned continuation of antibacterial antibiotics after the first neutrophil recovery (anc \> 1,000) * patients who are currently receiving or recently received (within 28 days) other investigational agents. * pregnant or breast feeding. the fda has not classified this agent into a specified pregnancy category. females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy

Keywords: aml allo-hct
thrombocytopenia in gestational period

Conditions: Immune Thrombocytopenia; Pregnancy

Summary: the project was undertaking by peking university people's hospital and other well-known hospitals in china. aims at evaluating efficacy and safety of dexamethasone in management of itp in pregnancy.

the investigators are undertaking a multicenter, open-labeled, pilot study of 50 itp patients in pregnancy from peking university people's hospital and other well-known hospitals in china. itp patients in pregnancy who failed to respond to prednisone, ivig and developed refractoriness to platelet transfusion will be given dexamethasone intravenously at a dose of 40mg every day for four days. platelet count, bleeding and other symptoms will be evaluated before and after treatment. adverse events will be recorded throughout the study.

Eligibility criteria:
inclusion criteria: * subject is between 20-50 years old. * after 12 weeks gestation. * diagnosed with itp meeting the diagnostic criteria for immune thrombocytopenia. * patients who have no response or relapsed after corticosteroid or ivig. * patients developed refractoriness to platelet transfusion. * to show a platelet count \< 30×10\^9/l, and with bleeding manifestations. * willing and able to sign written informed consent. exclusion criteria: * received chemotherapy or anticoagulants or other drugs affecting the platelet counts within 3 months before the screening visit. * received second-line itp-specific treatments (eg, cyclophosphamide, 6-mercaptopurine, vincristine, vinblastine, etc) within 3 months before the screening visit. * current hiv infection or hepatitis b virus or hepatitis c virus infections. * severe medical condition (lung, hepatic or renal disorder) other than chronic itp. * unstable or uncontrolled disease or condition related to or impacting cardiac function (e.g., unstable angina, congestive heart failure, uncontrolled hypertension or cardiac arrhythmia). * have a known diagnosis of other autoimmune diseases, established in the medical history and laboratory findings with positive results for the determination of antinuclear antibodies, anti-cardiolipin antibodies, lupus anticoagulant or direct coombs test. * patients who are deemed unsuitable for the study by the investigator.

Keywords: pregnancy immune thrombocytopenia dexamethasone
the impact of nasogastric tube gastric decompression on postoperative nausea and vomiting in orthognathic surgery

Conditions: Postoperative Nausea; Postoperative Vomiting

Summary: this study will compare the incidence of postoperative nausea and vomiting during the first 24 hours following corrective jaw surgery (orthognathic surgery) in patients with and without nasogastric tube gastric decompression.

postoperative nausea and vomiting (ponv) affects up to 60% of patients after orthognathic surgery. multiple complex mechanisms contribute to the development of ponv, but gastric pooling of blood is speculated to be the primary stimulus in this type of surgery. nasogastric (ng) tubes can be used for gastric decompression in the peri-operative period to evacuate gastric contents/blood, with an intent to minimize ponv. this study will directly compare the incidence of ponv in participants undergoing ng tube gastric decompression and those without ng tube gastric decompression in the first 24 hours after orthognathic surgery. participants will be randomized into two groups including no ng tube gastric decompression or ng tube gastric decompression throughout the surgery with removal one one hour postoperatively. the presence of early and/or delayed ponv will be monitored to determine the impact of ng tube gastric decompression. this study will also evaluate the impact of other variables including type of anesthesia, length of surgery, type of surgery and patient factors on the incidence of ponv in this study population.

Eligibility criteria:
inclusion criteria: * patients over the age of 16 at the time of consent undergoing orthognathic surgery for the correction of dentofacial deformities at the victoria general hospital during the study period. orthognathic surgery to include: 1. patients who receive single-jaw surgery (i.e. bsso \[bilateral sagittal split osteotomy\] only, or lefort only). 2. patients receiving double-jaw surgery (i.e. bsso and lefort). 3. patients undergoing a functional genioplasty in addition to another osteotomy (i.e. bsso and/or lefort). exclusion criteria: * patients will be excluded if they do not meet inclusion criteria or if they have risk factors known to directly impact ponv and/or cause delayed gastric emptying: 1. patients under the age of 16 at the time of consent. 2. patients contraindicated to undergo elective surgery, including pregnant patients. 3. patients undergoing a functional genioplasty procedure only. 4. patients taking glp-1 receptor agonists). 5. patients with known gastroparesis.

Keywords: nasogastric tube orthognathic surgery gastric decompression
induction of neutrophilic traps ( nets ) by the environment and infectious inflammatory lung cystic fibrosis

Conditions: Cystic Fibrosis

Summary: the study is defined in 3 stages of in vitro assays : phase 1 : secretion of nets in response to lung disease and their secretion of factors. this is a transversal study in which we compare : * producing nets (dna and proteases ) by neutrophils purified from sputum and blood of patients * producing nets (dna and proteases ) by purified neutrophils in the blood of patients and blood of control subjects phase 2: mechanisms of activation of nets secretory pathways . this phase will identify receptors (tlr ) involved in the secretion of nets and analyze the involvement of dependent transduction pathways calcium and pkc . it will be performed on control blood neutrophils. phase 3: analysis of cell death ( netose ) this is a transversal study that will analyze : the mode of cell death of neutrophils purified blood and sputum of patients and control blood neutrophils by flow cytometry and transmission electron microscopy .


Eligibility criteria:
inclusion criteria: patients : * men or women over 18 * patients with mucoviscidose in stable condition, i.e. not having presented an acute push of bronchopulmonary attack requiring a antibiothérapie or a hospitalization for treatment of its disease during the 2 previous weeks * signed consent volunteers : * men or women over 18 * without respiratory antecedent nor known respiratory pathology * signed consent exclusion criteria: patients : * in exclusion period of an other study volunteers : * in exclusion period of an other study * antibiotic treatment and/or anti-inflammatory drug (ains or corticoids) in the 2 weeks before inclusion in the study
percutaneous endoscopic biliary exploration in complex biliary stone disease

Conditions: Biliary Stones

Summary: patients with complex biliary stone disease are challenging to treat. the investigator present their experience in using urological interventions to treat challenging biliary stones. methods: fifteen patients with biliary calculi underwent 21 interventions using either extracorporeal shock wave lithotripsy (eswl), percutaneous transhepatic choledochoscopy, percutaneous transcystic choledochoscopy, or a combination of these.

the investigator conducted a retrospective review to investigate the outcomes of urological treatments for biliary calculi from january 1, 1999, to august 31, 2016, focusing on percutaneous endoscopic methods and/or eswl. the primary outcomes of interest were symptom- and stone-free rates, length of hospital stay, and complications. our institutional ethics review board approved the study (irb-2018-01-119). due to the retrospective nature of the study, the need for informed consent was waived. one endourologist evaluated all patients preoperatively. urological intervention techniques the three different approaches used (eswl, pthc, and ptcc) are described below.

Eligibility criteria:
inclusion criteria: * complete records exclusion criteria: * lost follow up